| Literature DB >> 36004348 |
Ke-Cheng Jiang1, Bei Lin1, Yu Zhang2, Ling-Qian Zhao1, Ding-Cun Luo2.
Abstract
Background: Accurate evaluation of the risk of papillary thyroid microcarcinoma (PTMC) is the key to treatment. However, the maximum diameter (MD), which is currently used in various staging systems, may not truly reflect the aggressiveness of multifocal tumors.Entities:
Keywords: multifocality; papillary thyroid microcarcinoma; propensity score matching analysis; total tumor diameter; tumor aggressiveness
Mesh:
Year: 2022 PMID: 36004348 PMCID: PMC9393720 DOI: 10.3389/fendo.2022.974755
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Comparison of baseline characteristics between multifocal PTMC with TTD >1 cm and TTD ≤1 cm before PSM.
| TTD > 1cm | TTD ≤ 1cm | P-value | |
|---|---|---|---|
| Age | 46.49 ± 12.32 | 47.48 ± 10.44 | |
| <55 | 129 (75%) | 286 (73.71%) | 0.748 |
| ≥55 | 43 (25%) | 102 (26.29%) | |
| Gender | |||
| Female | 134 (77.91%) | 330 (85.05%) | 0.039 |
| Male | 38 (22.09%) | 58 (14.95%) | |
| Maximum diameter | 7.56 ± 1.60 | 4.54 ± 1.53 | |
| 1 | 0 (0%) | 4 (1%) | <0.01 |
| 2 | 0 (0%) | 27 (6.96%) | |
| 3 | 1 (0.58%) | 73 (18.81%) | |
| 4 | 4 (2.33%) | 91 (23.45%) | |
| 5 | 13 (7.56%) | 94 (24.23%) | |
| 6 | 27 (15.70%) | 57 (14.69%) | |
| 7 | 35 (20.35%) | 31 (7.99%) | |
| 8 | 43 (25.00%) | 9 (2.32%) | |
| 9 | 25 (14.53%) | 2 (0.52%) | |
| 10 | 24 (13.95%) | 0 (0%) | |
| Number of tumor foci | 2.45 ± 0.70 | 2.06 ± 0.26 | |
| 2 | 111 (64.53%) | 386 (93.81%) | <0.01 |
| 3 | 49 (28.49%) | 23 (5.93%) | |
| 4 | 9 (5.23%) | 1 (0.26%) | |
| 5 | 2 (1.16%) | 0 (0%) | |
| 6 | 1 (0.58%) | 0 (0%) | |
| CLNM | |||
| Negative | 77 (44.77%) | 275 (70.88%) | <0.01 |
| Positive | 95 (55.23%) | 113 (29.12%) | |
| LLNM | |||
| Negative | 152 (88.37%) | 374 (96.39%) | <0.01 |
| Positive | 20 (11.64%) | 14 (3.61%) | |
| Capsular invasion | <0.01 | ||
| Negative | 121 (70.35%) | 340 (87.63%) | |
| Positive | 51 (29.65%) | 48 (12.37%) | |
| Extrathyroidal extension | <0.01 | ||
| Intrathyroidal | 129 (75.00%) | 354 (91.24%) | |
| Minimal extension | 39 (22.67%) | 34 (8.76%) | |
| Gross extension | 4 (2.33%) | 0 (0%) | |
| Risk stratification | <0.01 | ||
| Low | 117 (68.02%) | 359 (92.53%) | |
| Medium | 51 (29.65%) | 29 (7.47%) | |
| High | 4 (2.33%) | 0 (0%) | |
Comparison of baseline characteristics between multifocal PTMC and unifocal non-PTMC before PSM.
| Multifocal PTMC | Unifocal non-PTMC | P-value | |
|---|---|---|---|
| Age | 46.49 ± 12.32 | 46.27 ± 13.00 | |
| <55 | 129 (75%) | 311 (70.52%) | 0.268 |
| ≥55 | 43 (25%) | 130 (29.48%) | |
| Gender | |||
| Male | 134 (77.91%) | 334 (78.00%) | 0.979 |
| Female | 38 (22.09%) | 97 (22.00%) | |
| Maximum diameter | 13.19 ± 2.35 | 14.14 ± 2.78 | |
| 11 | 50 (29.07%) | 65 (14.74%) | <0.01 |
| 12 | 45 (26.16%) | 107 (24.26%) | |
| 13 | 17 (9.88%) | 57 (12.93%) | |
| 14 | 17 (9.88%) | 38 (8.62%) | |
| 15 | 10 (5.81%) | 77 (17.46%) | |
| 16 | 10 (5.81%) | 7 (1.59%) | |
| 17 | 10 (5.81%) | 13 (2.95%) | |
| 18 | 9 (5.23%) | 31 (7.03%) | |
| 19 | 2 (1.16%) | 4 (0.91%) | |
| 20 | 2 (1.16%) | 42(9.52%) | |
| CLNM | |||
| Negative | 77 (44.77%) | 212 (48.07%) | 0.461 |
| Positive | 95 (55.23%) | 229 (51.93%) | |
| LLNM | |||
| Negative | 152 (88.37%) | 340 (77.10%) | <0.01 |
| Positive | 20 (11.64%) | 101 (22.90%) | |
| Capsular invasion | |||
| Negative | 121 (70.35%) | 330 (74.83%) | 0.258 |
| Positive | 51 (29.65%) | 111 (25.17%) | |
| Extrathyroidal extension | |||
| Intrathyroidal | 129 (75.00%) | 380 (86.17%) | <0.01 |
| Minimal extension | 39 (22.67%) | 45 (10.20%) | |
| Gross extension | 4 (2.33%) | 16 (3.63%) | |
| Risk stratification | |||
| Low | 117 (68.02%) | 318 (72.11%) | 0.222 |
| Medium | 51 (29.65%) | 205 (23.81%) | |
| High | 4 (2.33%) | 18 (4.08%) | |
Figure 1Relationship between TTD and clinicopathological features in multifocal PTMC, including Age (A), Sex (B), CLNM (C), LLNM (D), ETE (E) and Risk stratification (F). TTD, total tumor diameter; PTMC, papillary thyroid microcarcinoma; CLNM, central lymph node metastasis; LLNM, lateral lymph node metastasis; ETE, extrathyroidal extension. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
Comparison of clinicopathological features between multifocal PTMC with TTD >1 cm and TTD <1 cm after PSM.
| TTD > 1cm | TTD ≤ 1cm | P-value | |
|---|---|---|---|
| Age | 46.37 ± 11.61 | 45.08 ± 9.33 | |
| <55 | 48 (77.42%) | 53 (85.48%) | 0.248 |
| ≥55 | 14 (22.58%) | 9(14.52%) | |
| Gender | |||
| Male | 53 (85.48%) | 54 (87.10%) | 0.794 |
| Female | 9 (14.52%) | 8 (12.90%) | |
| Maximum diameter | 6.44 ± 0.99 | 6.73 ± 0.98 | |
| 3 | 1 (1.61%) | 0 (0%) | 0.489 |
| 4 | 2 (3.23%) | 1(1.61%) | |
| 5 | 4 (6.45%) | 5 (8.06%) | |
| 6 | 22 (35.48%) | 17 (27.42%) | |
| 7 | 29 (46.77%) | 28 (45.16%) | |
| 8 | 3 (4.84%) | 9 (14.52%) | |
| 9 | 1 (1.61%) | 2 (3.23%) | |
| Number of tumor foci | 2.29 ± 0.58 | 2.15 ± 0.40 | |
| 2 | 111 (64.53%) | 386 (93.81%) | 0.350 |
| 3 | 49 (28.49%) | 23 (5.93%) | |
| 4 | 9 (5.23%) | 1 (0.26%) | |
| 5 | 2 (1.16%) | 0 (0%) | |
| CLNM | |||
| Negative | 24 (38.71%) | 36 (58.06%) | 0.031 |
| Positive | 38 (61.29%) | 26 (41.94%) | |
| LLNM | |||
| Negative | 58 93.55%) | 58 (93.55%) | 1 |
| Positive | 4 (6.45%) | 4 (6.45%) | |
| Capsular invasion | |||
| Negative | 44 (70.97%) | 56 (90.32%) | <0.01 |
| Positive | 18 (29.03%) | 6 (12.37%) | |
| Extrathyroidal extension | |||
| Intrathyroidal | 46 (74.19%) | 57 (91.94%) | 0.028 |
| Minimal extension | 15 (24.19%) | 5 (8.06%) | |
| Gross extension | 1 (1.61%) | 0 (0%) | |
| Risk stratification | |||
| Low | 117 (68.02%) | 359 (92.53%) | 0.041 |
| Medium | 51 (29.65%) | 29 (7.47%) | |
| High | 4 (2.33%) | 0 (0%) | |
Comparison of clinicopathological features between multifocal PTMC and unifocal non-PTMC after PSM.
| Multifocal PTMC | Unifocal non-PTMC | P-value | |
|---|---|---|---|
| Age | 46.51 ± 12.17 | 45.76 ± 11.78 | |
| <55 | 125 (75.30%) | 125 (75.30%) | 1 |
| ≥55 | 41(24.70%) | 41 (24.70%) | |
| Gender | |||
| Female | 134 (80.72%) | 136 (81.93%) | 0.979 |
| Male | 32 (19.28%) | 30 (18.07%) | |
| Maximum diameter | 13.08 ± 2.32 | 13.08 ± 2.32 | |
| 11 | 50 (30.12%) | 50 (30.12%) | 1 |
| 12 | 45(27.11%) | 45(27.11%) | |
| 13 | 17 (10.24%) | 17 (10.24%) | |
| 14 | 17 (10.24%) | 17 (10.24%) | |
| 15 | 10 (6.02%) | 10 (6.02%) | |
| 16 | 5 (3.01%) | 5 (3.01%) | |
| 17 | 9 (5.42%) | 9 (5.42%) | |
| 18 | 9 (5.42%) | 9 (5.42%) | |
| 19 | 2 (1.20%) | 2 (1.20%) | |
| 20 | 2 (1.20%) | 2 (1.20%) | |
| CLNM | |||
| Negative | 75 (45.18%) | 81 (48.80%) | 0.509 |
| Positive | 91(54.82%) | 85 (51.20%) | |
| LLNM | |||
| Negative | 147 (88.55%) | 132 (79.52%) | 0.025 |
| Positive | 19(11.45%) | 34 (20.48%) | |
| Capsular invasion | |||
| Negative | 118 (71.08%) | 145 (87.35%) | <0.01 |
| Positive | 48 (28.92%) | 21 (12.65%) | |
| Extrathyroidal extension | |||
| Intrathyroidal | 126 (75.90%) | 156 (93.95%) | <0.01 |
| Minimal extension | 37 (22.29%) | 6 (3.61%) | |
| Gross extension | 3 (1.81%) | 4 (2.41%) | |
| Risk stratification | |||
| Low | 115 (69.28%) | 133 (80.12%) | 0.046 |
| Medium | 48(28.92%) | 29 (17.47%) | |
| High | 3 (1.81%) | 18 (2.41%) | |
Logistic regression analysis of CLNM-related risk factors.
| Variate | Odds ratio | 95% CI | P-value | Variate | Odds ratio | 95% CI | P-value |
|---|---|---|---|---|---|---|---|
| MD | 1.24 | 1.134–1.356 | <0.01 | TTD | 1.17 | 1.106–1.231 | <0.01 |
| Age (vs <55) | 0.60 | 0.393–0.923 | 0.02 | Age (vs <55) | 0.60 | 0.391–0.926 | 0.02 |
| Sex (vs male) | 0.46 | 0.292–0.739 | 0.01 | Sex (vs male) | 0.49 | 0.302–0.780 | 0.01 |
| ETE (vs intrathyroidal) | ETE (vs intrathyroidal) | ||||||
| Minimal extension | 1.26 | 0.742–2.138 | 0.393 | minimal extension | 1.20 | 0.702–2.055 | 0.393 |
| Gross extension | 3.61 | 0.358–36.462 | 0.276 | gross extension | 3.61 | 0.245–27.479 | 0.276 |
Figure 2Comparison of prediction efficiency of TTD and MD for CLNM. TTD, total tumor diameter; CLNM, central lymph node metastasis; ETE, extrathyroidal extension.